NORML reports a pediatric clinical trial found a plant-derived cannabis preparation was safe and effective for autism, with disease severity falling about 2 points on a 7‑point scale after eight weeks.

Psychedelic Alpha reports that Risk Evaluation and Mitigation Strategies are likely to shape how FDA-approved psychedelic therapies are delivered. Here’s what to watch.